Alcon

Novartis acquired Alcon in stages between 2008 and 2011. After years of evaluating the business, Novartis fully separated Alcon in April 2019 via a spin-off that distributed Alcon shares to Novartis shareholders. Alcon is now a fully independent, publicly traded company listed on the SIX Swiss Exchange and NYSE. Novartis retains no controlling interest.

Alcon operates across two reportable segments. The Surgical segment sells intraocular lenses, phacoemulsification equipment, consumables used in cataract and vitreoretinal surgery, and implantable glaucoma devices. The Vision Care segment sells contact lenses — including its silicon hydrogel daily disposable Dailies Total1 — and over-the-counter eye drops such as Systane. Together the segments produced roughly $13 billion in annual revenue during recent fiscal years.

Alcon acquires clinically differentiated ophthalmic technologies that strengthen its surgical and pharmaceutical offerings. The 2022 acquisition of Aerie Pharmaceuticals provided commercial-stage glaucoma drugs, while the 2024 BELKIN Vision deal added automated direct selective laser trabeculoplasty technology. Both deals filled specific portfolio gaps rather than representing broad diversification plays.

Capital allocation decisions are overseen by CEO David J. Endicott and the executive leadership team, subject to board approval. The board includes members with deep experience across medtech, pharmaceuticals, and financial controls. Major strategic moves, such as the Aerie and BELKIN acquisitions, are disclosed via standard SEC and SIX regulatory filings.

Alcon maintains dual headquarters in Geneva, Switzerland, and Fort Worth, Texas. The Geneva office serves as the global operational headquarters, while Fort Worth retains significant commercial, R&D, and manufacturing functions. The dual structure reflects the company's Swiss incorporation and its deep historical and operational roots in the United States.